COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,235 Articles (22,733 medRxiv, 8,502 bioRxiv)

Most recent first Previous |  Page 134: Articles 1331-1340  | Next

Robust antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against a broad range of SARS-CoV-2 Omicron subvariants including JN.1, KP.3.1.1 and XEC
Uriu, K., Kaku, Y., Uwamino, Y., Fujiwara, H., Saito, F., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Sato, K.
10.1101/2024.11.20.624471 — Posted: 2024-11-20
Gut microbiome dysbiosis and immune activation correlate with somatic and neuropsychiatric symptoms in COVID-19 patients
Scalzo, P., Marshall, A., Soriano, S., Curry, K., Dulay, M., Hodics, T., Quigley, E. M., Treangen, T., Piskorz, M. M., Villapol, S.
10.1101/2024.11.18.24317428 — Posted: 2024-11-19
Low levels of neutralizing antibodies against SARS-CoV-2 KP.3.1.1 and XEC in serum from seniors in May 2024
Fossum, E., Vikse, E. L., Robertson, A. H., Wolf, A.-S., Rohringer, A., Trogstad, L., Mjaaland, S., Hungnes, O., Bragstad, K.
10.1101/2024.11.18.623742 — Posted: 2024-11-19
Clinical Features of Long COVID Patients Coinfected with Mycoplasma pneumoniae
Zhu, X., Li, Y., Wang, J., Gao, W.
10.1101/2024.11.16.24317441 — Posted: 2024-11-18
Upper Respiratory Tract Resistome exhibits SARS-CoV-2 specific antimicrobial resistance patterns
Tomar, S. S., Khairnar, K.
10.1101/2024.11.14.24317312 — Posted: 2024-11-18
Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection
Galipeau, Y., Castonguay, N., McCluskie, P. S., Sonoda, M. T., Keeshan, A., Collins, E., Arnold, C., Pelchat, M., Burns, K., Cooper, C., Langlois, M.-A.
10.1101/2024.11.18.24317488 — Posted: 2024-11-18
Immunosenescence profile is associated with increased susceptibility to severe COVID-19
Ventura, L. H. A., Torres, L., Camatta, G. C., Zamame, J., Coelho, M. M., Ramalho-Pinto, C. H., Gervazio, J., Caixeta, F., Nascimento, L., Oliveira, M. A., Martins, V. D., Oliveira, M. F., Costa, M. S., Sato, H. I., Guimaraes, H. C., Barbuto, R., Veiga, A. P., Ataide, N., Caetano, G. P., Rangon, S., Junior, M., Fortes, F. C., Zuccherato, L., Farias, E. S., Coelho, V., Avritchir, R., Souza, R., Ayupe, M. C., Loureiro, C., Neves, A. C. M., Passos, M. E., Leite, P., Teixeira, S., Tupinambas, U., Vilela, L. F., Silveira-Nunes, G., Maioli, T. U., Fonseca, D. M., Teixeira-Carvalho, A., Faria, A. M.
10.1101/2024.11.18.24317502 — Posted: 2024-11-18
Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC
Wang, Q., Guo, Y., Mellis, I. A., Wu, M., Mohri, H., Gherasim, C., Valdez, R., Purpura, L. J., Yin, M. T., Gordon, A., Ho, D. D.
10.1101/2024.11.17.624037 — Posted: 2024-11-18
Significantly enhancing antiviral efficacy by computational optimization and structural engineering of grafted nanobodies
HUO, L., Qin, Q., Tian, T., Zhang, X., He, X., Cao, Y., Zhang, T., Xu, Y., Huang, Q.
10.1101/2024.11.15.623776 — Posted: 2024-11-18
Chronic Viral Reactivation and Associated Host Immune Response and Clinical Outcomes in Acute COVID-19 and Post-Acute Sequelae of COVID-19
Maguire, C., Chen, J., Rouphael, N., Pickering, H., Phan, H. V., Glascock, A., Chu, V., Dandekar, R., Corry, D., Kheradmand, F., Baden, L. R., Selaky, R., McComsey, G. A., Haddad, E. K., Cairns, C. B., Pulendran, B., Fernandez-Sesma, A., Simon, V., Metcalf, J. P., Higuita, N. I. A., Messer, W. B., David, M. M., Nadeau, K. C., Kraft, M., Bime, C., Schaenman, J., Erle, D., Calfee, C. S., Atkinson, M. A., Brackenridge, S. C., Ehrlich, L. I. R., Montgomery, R. R., Shaw, A. C., Hough, C. L., Geng, L. N., Hafler, D. A., Augustine, A. D., Becker, P. M., Peters, B., Ozonoff, A., Kim-Schulze, S. H., Krammer, F., Bosinger, S., Eckalbar, W., Altman, M. C., Wilson, M., Guan, L., Kleinstein, S. H., IMPACC Network, , Smolen, K. K., Reed, E. F., Levy, O., Maecker, H., Hunt, P., Steen, H., Diray-Arce, J., Langelier, C. R., Melamed, E.
10.1101/2024.11.14.622799 — Posted: 2024-11-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).